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Scientific Abstract
There is significant variation in prescriptions among countries in clinical practice for the treatment of autism spectrum disorder (ASD). It has also been suggested that many people with mental health disorders in low/middle-income countries do not receive adequate treatment.
Hence, this study investigated psychopharmacological treatment patterns for ASD in thirty countries and the association between the country's income and ASD prescription rates.
The IMS Prescribing Insights database was used to investigate the prescription patterns for ASD treatment in 2007-2012. Data were obtained from 30 countries in the continents of Europe, Asia, Oceania, Central America, South America and Africa. The Gross Domestic Product (GDP) per capita was used as a proxy for the country's income. Spearman correlation was used to examine the association between prescription rate and GDP per capita.
The highest prescription rate was found in Europe (1.34-36.36/10,000) while the lowest prescription rates were found in Asian countries, such as Turkey, Indonesia, Saudi Arabia and Pakistan (0.04-0.82/10,000). The most common prescribed drug for ASD treatment in most of the countries was risperidone, but antidepressants and anti-epileptic drugs were also frequently prescribed. There was a significant positive correlation between GDP per capita and prescription rate (Spearman ρ=0.60; p=0.0011; 95%CI 0.27-0.81), that is, the higher the GDP per capita, the higher the prescription rate.
There are marked international differences in prescription rates for ASD, and this is partially accounted by economic factors. Future research should combine more data for ASD treatment to inform on the disparity of psychopharmacological treatment between countries.
(249 words)

Lay Abstract
There is wide variation in prescriptions among countries in clinical practice for the treatment of autism spectrum disorder (ASD). Many people with mental health disorders living in countries classified as low/middle income do not receive adequate treatment. Therefore, this study investigated psychopharmacological treatment patterns for ASD in thirty countries and the association between the country's income and ASD prescription rates.
An international healthcare information database (The IMS Prescribing Insights database) was used to investigate the prescription patterns for ASD treatment in 2007-2012. Data were obtained from 30 countries in the continents of Europe, Asia, Oceania, Central America, South America and Africa. The Gross Domestic Product (GDP) per capita was used as an indicator for the country's income. Spearman correlation, a statistical model, was used to examine the association between prescription rate and GDP per capita.
The highest prescription rate was found in Europe (1.34-36.36/10,000) while the lowest prescription rates were found in Asian countries, such as Turkey, Indonesia, Saudi Arabia and Pakistan (0.04-0.82/10,000). The most common prescribed drug for ASD treatment in most of the countries was risperidone, but antidepressants and anti-epileptic drugs were also frequently prescribed. The result implied the higher the GDP per capita, the higher the prescription rate between countries.
There are marked international differences in prescription rates for ASD, and this is
Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterised by impaired social and communicative behaviour as well as rigid and stereotyped patterns of behaviour (American Psychiatric Association, 1994; World Health Organization) . ASD is often comorbid in many individuals with mental health conditions including anxiety and mood disorders, attention-deficit hyperactivity disorder (ADHD), seizure disorder, sleep disorder and learning disabilities (Bradley & Bolton, 2006; MacNeil, Lopes, & Minnes, 2009; Matson & Neal, 2009; Simonoff et al., 2008; Souders et al., 2009) . Recent epidemiological studies report a prevalence of ASD of approximately 1.1% in children and adolescents in the United Kingdom (UK) and the United States (US) (Baird et al., 2006; Kogan et al., 2009 ), but the prevalence varies in different countries and across studies (Elsabbagh et al., 2012) . Approximately 70% of individuals with ASD suffer from additional mental conditions (Simonoff et al., 2008) .
The clinical management of ASD aims to maximise the affected individual's functional independence and quality of life, and to mitigate carer's distress and burden (Carbone, Farley, & Do, 2010; Myers, Johnson, 
& American Academy of Pediatrics Council on Children With
Disabilities, 2007) by minimising core symptoms, lowering the impact of associated mental health symptoms and reducing maladaptive behaviours (Cadman et al., 2012) . It includes educational and behavioural programmes and pharmacological treatment as an adjunct in the management of ASD (Myers et al., 2007) . There are currently no highly effective pharmacological treatments for the core symptoms of ASD, therefore current approaches target the minimisation of comorbid symptoms. Currently, however, there are limited practical guidelines for the pharmacological treatments of associated symptoms in children and 7 adolescents with ASD (Frazier et al., 2011) . In the US, only risperidone and aripiprazole are approved by the Food and Drug Administration (FDA) for the treatment of irritability in children with ASD Owen et al., 2009; Shea et al., 2004) . In other western countries, risperidone is also approved for the indication of behavioural disturbance among children and adolescents with ASD by the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK, and the Australian Therapeutic Goods Administration (TGA) (European Medicines Agency, 2007; World Health Organization, 2013) . Despite insufficient evidence on efficacy and long-term safety of psychotropic drugs for ASD treatment, various medications have been used for ASD treatment in clinical practice such as α-adrenergic agents, β blockers, mood stabilisers (or antiepileptics) and antipsychotics (Hollander, Phillips, & Yeh, 2003; McPheeters et al., 2011; Myers et al., 2007; Rosenberg et al., 2010) .
Previous studies have estimated that approximately 27% to 60% of children and adolescents received at least one medication for ASD treatment in the US and Canada (Coury et al., 2012; Frazier et al., 2011; Mandell et al., 2008) . In the UK, a study using a primary care database reported approximately 29% (1,619/5,651) of young people aged 0-24 years with ASD received psychotropic drugs; and the commonly prescribed drug classes were sleep medications (9.7%), stimulants (7.9%), and antipsychotics (7.3%) (Murray et al., 2013) . Although previous studies have demonstrated the prescription patterns of ASD treatment in the US and the UK, the generalisability of the findings to other countries is unknown. This is of relevance due to geographic and cultural differences, as well as potential variations in clinical practice [22] . A face-to-face interview survey study conducted by the World Health Organisation (WHO) in 17 countries showed that the proportion of patients with mental health disorders (e.g. anxiety, mood and substance disorders) receiving either pharmacotherapy (≥1 month of a medication, plus ≥ 4 visits to medical doctor) or psychotherapy (≥ 8 visits with any professional) was smaller in low and middle-income countries as compared with high-income countries (Wang et al., 2007) . In addition, it suggested that the majority of people with mental health disorders in low/middle income countries do not receive the treatment that they need (Lund et al., 2012) . In our previous work, we demonstrated significant variation in psychopharmacological prescription patterns between 2010 and 2012 in children and adolescents with ASD across ten countries (Hsia et al., 2013) . However, we did not investigate the extent to which a country's income is associated with variation in drug treatment. Also to date, there are very limited cross-national studies on ASD treatment available. Therefore, we conducted a descriptive comparison of prescription rates in 30 countries that previously had no published data. We investigated whether a country's income was associated with ASD treatment.
Method
Data source
This was a descriptive study using the IMS Prescribing Insights (MIDAS) database to investigate prescriptions issued for patients with a diagnosis of ASD in 30 countries. The IMS MIDAS database is an audit drawn from a representative sample of practitioners in each country and contains diagnoses and prescription data from different countries (Wong & Murray, 2005) . The prescription data of sampled doctors were adjusted according to different stratification methods (see Table 1 ), and a projected national total of prescriptions data per year was calculated for each country. Table 1 summarises the details of data collection including the number of doctors involved, stratification methods, and reporting time for each country. Previous studies have used the MIDAS database to investigate the prescription trends and patterns of psychotropic prescriptions (Balkrishnan, Phatak, Gleim, & Karve, 2009; Livermore et al., 2006; Wong, Murray, Camilleri-Novak, & Stephens, 2004) . Therefore, this database is suitable for investigating the prescription patterns at a global level.
Study population
Prescriptions for patients with a diagnosis of ASD were identified using International Turkey, Saudi Arabia), two South American countries (Colombia, Venezuela), two countries in the Oceania (Australia, New Zealand), and two African countries (Egypt, South Africa). The prescription data of Central America were drawn from sampled physicians in Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica, and Panama then adjusted according to the stratifications to obtain six countries' projected prescriptions. Therefore, "Central America" was used to represent six countries' projected prescription data throughout this study.
Drug prescribing
We used several drug categories to classify ASD treatment: (1) stimulants (atomoxetine, dexamfetamine, methylphenidate), (2) antidepressants,
antipsychotics,
antiepileptics/mood stabilisers, (5) benzodiazepines, (6) sleep medications (including melatonin), (7) clonidine, (8) beta-blockers, (9) antiparkinson medication, and (10) anxiolytics.
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Estimated prescription rate
The "average annual projected number of prescriptions" was calculated by the summation of the projected number of prescriptions between 2007 and 2012 (inclusive); followed by the division of the sum by 6. The estimated annual prescription rates were calculated by dividing "average annual projected number of prescriptions" by the estimated annual population. 
Results
There was a wide range of estimated prescription rates in different countries between 2007 and 2012 ( Table 2 ). The European countries were found to have highest prescription rate (1.34-36.36/10,000). The lowest prescription rates were observed in Egypt (0.74/10,000), Venezuela (0.83/10,000) and Asian countries such as Turkey, Saudi Arabia, Indonesia and Pakistan (0.04-0.82/10,000). There was a significant positive relation between GDP per capita and prescription rate (Spearman's coefficient ρ=0.60; p=0.0011 ( Figure 2 ). In general, countries with low GDP per capita have low estimated prescription rates. However, it is important to note that this was not universally the case. For instance, some countries (e.g. Switzerland, Austria, Finland and Australia) have high GDP per capita but low estimated prescription rates for ASD treatment; in contrast Colombia and Thailand have low GDP per capita but high estimated prescription rates. Table 3 shows the most common drug prescribed for ASD treatment in each country.
Risperidone was a commonly prescribed drug in all countries except Finland. Buspirone (an anxiolytic) was the drug most commonly prescribed for ASD treatment in Finland. Stimulants (methylphenidate, atomoxetine) and anti-epileptic drugs (e.g. lamotrigine, carbamazepine, valproic acid) were also prescribed for treatment in most countries.
Discussion
There is considerable variation in prescription rates among countries. The variation of psychopharmacological prescription patterns may be explained by a number of factors such as socioeconomic status, awareness or levels of knowledge about ASD, perceptions towards ASD treatment and access to health services. In general, antipsychotic drugs were the most frequently prescribed drug class for ASD and risperidone was commonly prescribed in all countries. There are two FDA-approved medications (risperidone and aripiprazole) licensed for the treatment of irritability or aggression in patients with ASD. Risperidone is also labelled for the treatment of behavioural problems in people with ASD in some countries including European countries. In addition, as risperidone is off-patent and the generic products are more affordable than aripiprazole, this may explain its popularity as ASD treatment.
Stimulants, antiepileptics, mood stabilisers, and antidepressants were also frequently prescribed for ASD treatment in our study. However, as we do not have the information on the individuals' co-morbidities, we do not know whether these drugs are being used for the treatment of ASD symptoms or other psychiatric co-morbidities. Since there are very limited data on the efficacy and long term adverse reactions of these drugs in patients with ASD, further research is warranted.
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There was significant association between psychotropic drug use for ASD treatment and GDP per capita. Our results indicate that in general countries with low GDP tend to have low prescription rates. Low prescription rates found in low/middle countries could be due to smaller health budgets to mental health policy and services. A study involving 191 countries reported that a smaller proportion of health budget was allocated to mental health in lower income countries compared with higher income countries. In addition, many low income countries relied on out-of-pocket expenditure (Saxena, Sharan, & Saraceno, 2003) . In comparison to tax-based and insurance-based for health care financing, out-of-pocket expenditure could create financial burdens for the patients and their families, and thus may lower the rate of receiving services in the low/middle income countries. Another survey reported a similar association between the overall expenditures on health care and percentage of patients receiving services (Wang et al., 2007 (Wang et al., 2007) .
Reduced follow-up care could also contribute to the lower prescription rates in low/middle income countries. Further research is needed to obtain more detailed data to investigate the 14 association between ASD treatment and health care expenditures on mental health in different countries.
To our knowledge, this is the largest multi-national comparison of psychopharmacological use in ASD treatment. However, there are notably several limitations. First, as IMS MIDAS is not a patient-based medical record database, we were unable to report the number of patients who visited physicians for ASD treatment in this study. Consequently, we cannot estimate the treatment rates in patients with ASD. Second, our stratified sampling was intended to provide a representative sample for each country. However some patients may be under the care of psychiatrists for the management of ASD-related symptoms and the sample of clinicians we had access to only represent a small percentage of psychiatrists. Therefore, the audit may have underestimated the number of prescriptions. Third, we were unable to obtain data on co-morbidities, so we do not know whether psychotropic drugs were prescribed for the treatment of core symptoms of ASD or for other psychiatric co-morbidities. Lastly, despite the significant positive correlation between GDP per capita and prescription rate for ASD treatment, potential confounders could not be adjusted for due to limited information in the dataset (e.g. age of the patients and the use of complementary/ 'alternative' treatments).
Conclusion
There is wide variation in the psychopharmacological treatment of ASD among countries. In general, European countries have the highest prescription rate compared to those in Asian regions. Also there is an association between psychotropic drug use and GDP per capita in most (but not all) countries. Future research should incorporate more data including treatment rates, age of the patients and the use of complementary or alternative treatments for ASD in different countries to develop an in-depth understand of the disparity of psychopharmacological treatment between countries. Spearman's coefficient ρ=0.60; p=0.0011 
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